USPTO Examiner CURRENS GRANT CARSON - Art Unit 1651

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18637707METHODS FOR QUANTIFYING FRATAXIN ACTIVITYApril 2024May 2025Allow1310YesNo
18627241SPORE-BASED PROBIOTIC SUPPLEMENTATION IN DOGS AND CONTROL OF ENDOTOXEMIAApril 2024April 2025Allow1210NoNo
18594570EDIBLE PLANT PARTS ENRICHED WITH PROBIOTIC BACTERIAMarch 2024June 2025Allow1510YesNo
18406008TREATMENT OF VON WILLEBRAND DISEASEJanuary 2024January 2025Allow1210NoNo
18492533NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHEOctober 2023January 2025Abandon1510NoNo
18490629PROBIOTIC COMPOSITIONOctober 2023April 2025Allow1820NoNo
18351961NOVEL BACTERIOPHAGE THAT LYSES ACINETOBACTER GENUS BACTERIA HAVING RESISTANCE TO ANTIBIOTICSJuly 2023September 2024Abandon1401NoNo
18270925COMPOSITION COMPRISING THREE LACTOBACILLUS SP. STRAINS, AND USE THEREOFJuly 2023March 2025Allow2030YesNo
18336973APPLICATION OF MEDICAL CELL CMU-PB-7 IN PREPARATION OF BLOOD LIPID-LOWERING DRUGSJune 2023February 2024Allow820NoNo
18317309DYSOSMOBACTER, A NOVEL BACTERIAL GENUS OF THE GASTROINSTESTINAL MICROBIOTA AND USES THEREOFMay 2023April 2025Allow2321YesNo
18314864Chimeric endolysin polypeptide, cluster 3bMay 2023September 2024Allow1621YesNo
18301188THERAPEUTIC BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTIONApril 2023November 2024Allow1911NoNo
18133168PHARMACEUTICAL COMPOSITION, PACKAGE AND METHOD FOR PRODUCING THE SAMEApril 2023December 2024Allow2020YesNo
18053245BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONSNovember 2022May 2024Abandon1811NoNo
18049770NANO-VESICLES DERIVED FROM GENUS SPHINGOMONAS BACTERIA AND USE THEREOFOctober 2022December 2023Allow1310YesNo
17950886COMPOSITION FOR SUPPRESSING FAT ACCUMULATIONSeptember 2022September 2024Abandon2420NoNo
17818834MICROBIAL COMPOSITIONS AND METHODS OF USE FOR CANINE ENTEROPATHY AND DYSBIOSISAugust 2022June 2024Allow2331YesNo
178131903D PRINTED, FREEZE-DRIED HYDROGELS AND METHODS OF MAKING AND USING THE SAMEJuly 2022May 2025Allow3441YesNo
17770042COMPOSITIONS FOR GUT HEALTHApril 2022November 2024Allow3110YesNo
17712951METHODS AND PROCESSES FOR TREATING THE GLABELLAApril 2022April 2025Abandon3610NoNo
17604972MICROBIOTA TRANSFER THERAPY FOR PITT HOPKINS SYNDROMEOctober 2021December 2024Allow3811YesNo
17604960LACTOBACILLUS RHAMNOSUS LRH05 ISOLATE, AND COMPOSITION INCLUDING THE SAME AND USE THEREOFOctober 2021November 2024Allow3710NoNo
17602131METHODS OF INCREASING THE GERMINATION RATE OF FUNGAL SPORESOctober 2021April 2025Abandon4210NoNo
17490734USE OF FAECALIBACTERIUM PRAUSNITZII IN PREPARATION OF MEDICINE FOR TREATING PATHOLOGICAL VENTRICULAR REMODELING AND/OR HEART FAILURE FOLLOWING MYOCARDIAL INFARCTIONSeptember 2021March 2023Allow1710YesNo
17478017COMPOSITIONS AND METHODS FOR CONTROLLING MYCOTOXIN PRODUCTIONSeptember 2021April 2024Abandon3110NoNo
17386917BIOLUMINESCENT SENSOR FOR ISOTHIOCYANATESJuly 2021June 2024Allow3411YesNo
17421965CHLAMYDOMONAS MUTANT AND USE THEREOFJuly 2021March 2025Allow4411YesNo
17354531NOVEL KIMCHI-DERIVED LACTOBACILLUS FERMENTUM STRAIN WITH EXCELLENT ANTI-INFLAMMATORY ACTIVITY AND COMPOSITION INCLUDING SAME FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASESJune 2021January 2023Abandon1901NoNo
17413306COMPOSITION FOR THE PREVENTION AND TREATMENT OF SKIN DISEASESJune 2021October 2024Abandon4001NoNo
17344372SWINE ORIGIN PROBIOTICS THAT PROMOTE HEALTH AND GROWTH PERFORMANCE IN PIGSJune 2021October 2024Allow4040YesYes
17298386BOTULINUM TOXIN-STABILIZING LIQUID COMPOSITIONMay 2021August 2024Abandon3910NoNo
17291313COMBINATION THERAPIES OF MICROORGANISMS AND IMMUNE MODULATORS FOR USE IN TREATING CANCERMay 2021August 2024Abandon3901NoNo
17246977COMPOSITION FOR PROMOTING DEFECATION AND USE THEREFORMay 2021January 2023Allow2110YesNo
17246124ADMINISTRATION OF SEGMENTED FILAMENTOUS BACTERIA WITH A HUMIC SUBSTANCEApril 2021March 2024Abandon3421NoNo
17281926BACTERIAL STRAINS OF THE LACTOBACILLUS PARACASEI SPECIES FOR USE, ORAL OR TOPICAL, IN THE TREATMENT OF DISORDERS OF THE FEMALE UROGENITAL TRACTMarch 2021October 2022Abandon1821YesNo
17275839ANIMAL FEED COMPOSITIONS AND USES THEREOFMarch 2021December 2023Abandon3401NoNo
17185256MICROBIAL FEED SUPPLEMENT COMPOSITION AND METHODFebruary 2021February 2025Allow4851YesNo
17269135METHODS AND COMPOSITIONS FOR HONEY BEE HEALTHFebruary 2021July 2024Allow4121YesNo
17166490TREATMENT OF VON WILLEBRAND DISEASEFebruary 2021October 2023Allow3320YesNo
17166015COMPOSITIONS FOR GUT HEALTHFebruary 2021November 2024Allow4511YesNo
17265169NOVEL NICOTINE DEGRADING ENZYME VARIANTSFebruary 2021February 2025Allow4821YesNo
17153761NUCLEIC ACID MODIFICATION WITH TOOLS FROM OXYTRICHAJanuary 2021June 2025Abandon5321NoNo
17146674TISSUE STAINING COMPOSITION AND TISSUE STAINING METHOD USING SAMEJanuary 2021November 2023Allow3421YesNo
17142601QUANTITATIVE CHARACTERIZATION OF ALGAL BIOMASS BIOMOLECULESJanuary 2021October 2024Allow4531YesNo
17258256DYSOSMOBACTER, A NOVEL BACTERIAL GENUS OF THE GASTROINTESTINAL MICROBIOTA AND USES THEREOFJanuary 2021February 2023Allow2521YesNo
17141692BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIAJanuary 2021July 2024Abandon4310NoNo
17133660HYBRID HYDROGEL CARRIER FOR HIGH-SALINITY WASTEWATER TREATMENT AND PREPARATION METHOD THEREOFDecember 2020May 2025Abandon5241YesNo
17132270Method for Enzymatic Sulfurylation of Alcohols and Amines Using Bacterium of the Family EnterobacteriaceaeDecember 2020June 2024Allow4110YesNo
17252998LYSIN CF-301 RESENSITIZES METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUA (MRSA) TO PENICILLIN DERIVATIVES AND FIRST GENERATION CEPHALOSPORINSDecember 2020June 2024Abandon4210NoNo
17105149METHODS FOR QUANTIFYING FRATAXIN ACTIVITYNovember 2020February 2024Allow3911YesNo
16951050METHODS AND COMPOSITIONS FOR DETECTING BETA-HYDROXYBUTYRATE IN BIOLOGICAL FLUIDSNovember 2020October 2023Abandon3411NoNo
16950323Use of Lactobacillus Plantarum S58 in Preparation of Product for Alleviating Spicy Food-Induced Damage to Digestive SystemNovember 2020December 2022Abandon2520NoNo
17085350NOVEL BACTERIOPHAGE THAT LYSES ACINETOBACTER GENUS BACTERIA HAVING RESISTANCE TO ANTIBIOTICSOctober 2020August 2023Abandon3411NoNo
17050982MICROBIALS FOR FEEDOctober 2020November 2023Allow3721YesNo
17078376RECOMBINANT L-ASPARAGINASEOctober 2020July 2024Allow4540YesNo
17048930COMPOSITION FOR TYPE IV ALLERGYOctober 2020December 2022Abandon2610NoNo
17048924COMPOSITION FOR SUPPRESSING FAT ACCUMULATIONOctober 2020April 2023Abandon3020NoNo
17071956MICRO-ORGANISMAL PRODUCT AND METHOD FOR TREATING SICKLE CELL DISEASEOctober 2020January 2023Abandon2710NoNo
17046103EDIBLE PLANT PARTS ENRICHED WITH PROBIOTIC BACTERIAOctober 2020December 2023Allow3931YesNo
17060175COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF PATHOGENIC ESCHERICHIA COLIOctober 2020February 2023Allow2821YesNo
17043545COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASESSeptember 2020February 2024Abandon4021NoNo
15733682TREATMENT OF A CANCER BY MICROBIOME MODULATIONSeptember 2020June 2024Abandon4521NoNo
17033195BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIASeptember 2020July 2024Abandon4611NoNo
17040676Composition for Inactivating Smell ComponentSeptember 2020March 2024Abandon4201NoNo
17023097SPORE-BASED PROBIOTIC SUPPLEMENTATION IN DOGS AND CONTROL OF ENDOTOXEMIASeptember 2020December 2022Abandon2721YesNo
17006685NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHEAugust 2020July 2023Allow3520YesNo
17006430COMPOSITIONS COMPRISING BACTERIAL SPECIES AND METHODS RELATED THERETOAugust 2020February 2024Allow4231YesNo
16975546PHARMACEUTICAL COMPOSITION, PACKAGE AND METHOD FOR PRODUCING THE SAMEAugust 2020January 2023Allow2820YesNo
16987061COMPOSITION, PRODUCTION METHOD FOR PRODUCING THE SAME, AND METHOD OF PREVENTING CAKINGAugust 2020October 2023Abandon3830YesNo
16965471POSTBIOTIC-BASED COMPOSITION FOR THE MODULATION OF IMMUNE SYSTEM ACTIVATION AND PROTECTION OF MUCOSAL BARRIERSJuly 2020August 2024Allow4831YesNo
16939170COMPOSITIONS AND RELATED METHODS FOR AGRICULTUREJuly 2020June 2025Abandon5841NoYes
16937248USE OF THE TREATMENT OR IMPROVEMENT OF SLEEP DISORDERS BY LACTOBACILLUS BREVIS PROGA28 AND/OR ITS METABOLITESJuly 2020August 2022Allow2520YesNo
16962976LACTOBACILLUS PLANTARUM KBL396 STRAIN AND USE THEREOFJuly 2020November 2022Allow2820YesNo
16960318PROBIOTIC BACTERIA FOR FISHJuly 2020July 2025Allow6041YesNo
16959666THERAPEUTIC BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTIONJuly 2020January 2023Allow3010YesNo
16954383ANIMAL FEED COMPOSITIONS AND USES THEREOFJune 2020June 2023Abandon3611NoNo
16771075COMPOSITIONS AND METHODS FOR SUPPRESSING PATHOGENIC ORGANISMSJune 2020March 2024Allow4531YesNo
16770432BACTERIOPHAGE TREATMENT FOR ACNE AND BIOFILMSJune 2020January 2024Abandon4421NoNo
16766389A COMPOSITION COMPRISING A COHORT OF BACTERIAMay 2020April 2024Abandon4730NoNo
16762260COMPOSITION FOR IMPROVING THE WELL-BEING OF ANIMALSMay 2020November 2022Abandon3020NoNo
16760590DIAGNOSTIC AND THERAPEUTIC METHODS FOR TYPE 2 DIABETESApril 2020June 2022Abandon2501NoNo
16759201FORMULATIONS COMPRISING GLUCOCEREBROSIDASE AND ISOFAGOMINEApril 2020November 2023Abandon4331NoNo
16755801PROBIOTIC COMPOSITIONApril 2020July 2023Allow3931YesNo
16840334COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF PATHOGENIC ESCHERICHIA COLIApril 2020November 2022Allow3221YesNo
16753388BOTULINUM NEUROTOXIN A SUBTYPE 6 AND PHARMACOLOGICAL METHODS OF USEApril 2020April 2024Abandon4831YesNo
16652608Pasture Treatments for Enhanced Carbon Sequestration and Reduction in Livestock-Produced Greenhouse Gas EmissionsMarch 2020July 2023Allow3921YesNo
16816903METHOD FOR TREATING AND/OR PREVENTING COCCIDIOSISMarch 2020August 2022Abandon2920NoNo
16639378NOVEL METHODS FOR THE TARGETED INTRODUCTION OF VIRUSES INTO CELLS AND TISSUESFebruary 2020July 2023Abandon4120NoNo
16788990COMPOSITION FOR COMPETITIVE INHIBITION OF PATHOGENS AND RESTORATION OF MICROBIAL ECOLOGICAL BALANCEFebruary 2020May 2024Allow5141YesNo
16788257Combined Multistage Microbial Preparations and Method of Their ApplicationFebruary 2020August 2022Abandon3011NoNo
16779776METHOD FOR DETECTING DIFFERENT PROPERTIES IN A MICROORGANISM POPULATION BY OPTICALLY INDUCED DIELECTROPHORETIC FORCEFebruary 2020November 2022Abandon3310NoNo
16750148SAMPLE PROTECTION METHODJanuary 2020March 2023Allow3810YesNo
16631491NANO-VESICLES DERIVED FROM GENUS SPHINGOMONAS BACTERIA AND USE THEREOFJanuary 2020August 2022Allow3111NoNo
16677815METHOD OF PRODUCING HIGH FUCOXANTHIN-CONTAINING ALGANovember 2019January 2023Abandon3811NoNo
16611877VIBRIO PARAHAEMOLYTICUS BACTERIOPHAGE VIB-PAP-7 AND USE OF SAME FOR INHIBITING VIBRIO PARAHAEMOLYTICUS BACTERIA PROLIFERATIONNovember 2019March 2023Allow4130YesNo
16607921Methods and Compositions for Storing BacteriaOctober 2019January 2023Abandon3921NoNo
16597509TOBACCO MOSAIC VIRUS DELIVERY OF MITOXANTRONE FOR CANCER THERAPYOctober 2019June 2024Abandon5750NoNo
16500558MICROBIAL INSECTICIDE FOR CONTROL OF MULBERRY THRIPSOctober 2019December 2024Abandon6070YesNo
16582053LUNG PROTEASE NANOSENSORS AND USES THEREOFSeptember 2019August 2024Allow5821YesNo
16487628METHODS FOR IMPROVING FILTERABILITY OF POLYSACCHARIDE-PROTEIN CONJUGATE REACTIONSAugust 2019May 2024Abandon5630NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CURRENS, GRANT CARSON.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CURRENS, GRANT CARSON - Prosecution Strategy Guide

Executive Summary

Examiner CURRENS, GRANT CARSON works in Art Unit 1651 and has examined 109 patent applications in our dataset. With an allowance rate of 52.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner CURRENS, GRANT CARSON's allowance rate of 52.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CURRENS, GRANT CARSON receive 1.93 office actions before reaching final disposition. This places the examiner in the 62% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CURRENS, GRANT CARSON is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +76.5% benefit to allowance rate for applications examined by CURRENS, GRANT CARSON. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.6% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 48.5% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.8% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.5% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.